Esoterix Inc. establishes new molecular genetics lab

Esoterix Inc. (Austin, TX) announced today the development of Esoterix Molecular Genetics. Esoterix Molecular Genetics will stand apart from other genetic laboratories with its unique capability to integrate clinical laboratory data for information, coupled with a mission to educate clients in the full breadth of what genetics can do for patient care. The facility is currently under construction in Minneapolis and will be open for business in August.

Vice President Ron McGlennen, MD, leads Esoterix Molecular Genetics. McGlennen is a diplomat of the American Board of Medical Genetics and the Board of Anatomic and Clinical Pathology. McGlennen received his undergraduate degree in mathematics from Northwestern University and his MD from the University of Minnesota Medical School. He serves on the editorial boards of Human Pathology, Molecular Diagnosis, Clinical Chemistry and the Journal of Laboratory and Clinical Medicine.

"Esoterix Molecular Genetics provides innovative, cost-effective testing in the areas of molecular diagnostics, including those for constitutional genetics (inherited disorders), acquired genetic diseases (such as cancer) and disorders of genetic predisposition (such as thrombophilia)," adds McGlennen.

Esoterix Molecular Genetics was formed through a new venture agreement with Access Genetics and is part of the Esoterix Inc. family of laboratories. Founded in 1995, Esoterix, Inc. is a unique company providing technology-based laboratory services and information solutions to enhance healthcare providers' ability to manage and care for patients. Esoterix's testing services include expertise in Allergy and Asthma, Coagulation/Cardiology, Endocrinology, Infectious Disease, Oncology and Toxicology. Esoterix also has a central laboratory, Esoterix Center for Clinical Trials, dedicated to biopharmaceutical research. Esoterix has 580 employees and is privately funded through Behrman Capital of New York. (www.esoterix.com)

Source: Esoterix Inc.